Entweder 10000% oder Totalverlust
galgenhumor gehört bei sowas dazu...
Scheissaktie ist das!!!
Optionen
| Boardmail an "Realer" |
Wertpapier: CALYPTE BIOMED. DL-.0 |
jetzt noch Warmduscher-News und dann hattet ihr wieder recht, heute müssen wir die 0,024$ halten dann bin ich wieder guter dinge, bin ich immer ich weiß,
gruß werweiß
seid ihr alle in den ohnmacht gefallen, keine angst so schnell gehts auch wieder nicht mit caly, will nur ein bißchen auf die euphorie-bremse drücken, kann mal jemand die nicht mal so schlechten news hier reinsetzen weiß nicht wie es geht
gruß werweiß der partymaker
4/10/2003 9:04:00 AM
***************************************
Follow-up:
Quotes & News:
Cambridge Biotech Serum Western Blot Update; Adaltis U.S. Inc. Grows Their Customer Base for Calypte Product
4/10/2003 9:04:00 AM
ALAMEDA, Calif., Apr 10, 2003 (BUSINESS WIRE) -- Calypte Biomedical Corporation (CALY) , the developer and marketer of the only two FDA approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA approved serum HIV-1 antibody Western blot supplemental test, said today that its decision to establish a distribution relationship with Adaltis U.S. Inc. has opened up new markets for its Cambridge Biotech serum Western blot product, without negatively impacting the Company`s direct customer base.
Richard Eckloff, Vice President and General Manager, Adaltis U.S. Inc., stated, "Nine months ago we welcomed the opportunity to represent Calypte`s serum Western blot product. Today we believe that this was a sound business decision, and we remain committed to continuing to grow this business.
"We are able to offer an established product with an excellent reputation in a category with only one other competitor and have found that many customers and potential accounts consider the quality of the product to be a gold standard. That quality message along with the promise of guaranteed delivery has allowed us to capture in excess of 30 accounts. Also, we have well over 50 prospective accounts and are in discussions with several national reference labs," Eckloff added.
"We are committed to the serum Western blot business and are pleased with the outlook presented by Adaltis," said Nancy Katz, President and CEO for Calypte. "We believe that the guaranteed delivery message used by Adaltis is meaningful to customers since we know that this industry has historically been plagued with extensive backorders. Calypte has established an excellent track record with Adaltis by providing on time delivery of 100% of Adaltis` scheduled orders and we have accomplished this without impacting our direct customers."
Adaltis U.S. Inc. actively distributes and markets the Cambridge Biotech serum Western blot kit via marketing and promotion programs and their sales organization.
About Adaltis U.S. Inc.
Adaltis is an international privately held diagnostic group of companies that develop, manufacture and distribute diagnostic products in select markets. Adaltis U.S. Inc. provides specialized diagnostic products through its direct sales and support organization maintaining a high quality standard of products and services it offers. Adaltis U.S. Inc. is headquartered in Allentown, Pennsylvania.
About Calypte Biomedical
Calypte Biomedical Corporation, headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte`s tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners. Current product labeling including specific product performance claims can be found on our website at www.calypte.com.
Statements in this press release that are not historical facts are forward-looking statements, including statements regarding announcements of financial results and presentations by the Company. Such statements reflect management`s current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company`s expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company`s success are more fully disclosed in the Company`s most recent public filings with the U.S. Securities and Exchange Commission ("SEC", including its annual report on Form 10-K for the year ended December 31, 2002 and its subsequent filings with the SEC.
Calypte Biomedical Corporation
Pamela South, 510/749-5100
psouth@calypte.com
or
Sitrick And Company (Investor Relations)
Joe Bunning, 310/788-2850
email: joe_bunning@sitrick.com
CALY Last: 0.03 Change: +0.01 +28.89% Volume: 4,217,400 1:52pm
4/10/2003 Choose your broker
Open: 0.02 Yield: n/a Shares Out: 195.44M
High: 0.03 P/E Ratio: n/a Market Cap: 5.67M
Low: 0.02 EPS: -0.17 52wk High: 7/9/2002 0.43
Bid: 0.03 Ex Date: n/a 52wk Low: 4/18/2002 0.01
Ask: 0.03 Dividend: n/a Avg Volume: 5.40M
Add to Alerts Add to My Portfolio New: Check out The Calandra Report
wie das geht, und was du von diesen news hältst, und wenn du jetzt noch eine
frau bist, dann wäre der abend gerettet, *ggg, kommst du auch zur fete ???
Mit den News bin ich noch beschäftig(translate und so)Muss aber irgendwas gutes sein.
cu
bei Start über 0,027 $ sehe ich gute Chancen, aber es müßten nochmal news kommen
dann gehts up !!!!!11
geschlossen mit 0,026 $ !!!
Aber heute ist ein guter Tag, advent advent ein lichtlein brennt erst eins
dann zwei dann drei dann vier dann steht die party vor der tür !!!
viele reden hier von kerzen, und die könnten noch recht behalten
gruß werweiß
heutiger us-start 0,029
Calypte Biomedical Corp. Quarterly Income Statement Display Annual Data
More filings for Calypte Biomedical Corp. available from EDGAR Online. Get a Free Trial to EDGAR Online Premium
Income Statement Balance Sheet Cash Flow Statement
Period Ending: Dec 31, 2002 Sep 30, 2002 Jun 30, 2002 Mar 31, 2002
Total Revenue $809,000 $493,000 $1,209,000 $1,159,000
Cost Of Revenue $1,593,000 $1,542,000 $1,397,000 $1,630,000
Gross Profit ($784,000) ($1,049,000) ($188,000) ($471,000)
Operating Expenses
Research And Development $289,000 $219,000 $180,000 $241,000
Selling General And Administrative Expenses $4,139,000 $1,565,000 $2,087,000 $1,215,000
Non Recurring N/A N/A N/A N/A
Other Operating Expenses N/A N/A N/A N/A
Operating Income ($5,212,000) ($2,833,000) ($2,455,000) ($1,927,000)
Total Other Income And Expenses Net ($17,000) $12,000 $15,000 $9,000
Earnings Before Interest And Taxes ($5,229,000) ($2,821,000) ($2,440,000) ($1,918,000)
Interest Expense $993,000 ($1,326,000) $2,492,000 $47,000
Income Before Tax ($6,222,000) ($1,495,000) ($4,932,000) ($1,965,000)
Income Tax Expense N/A N/A N/A $2,000
Equity Earnings Or Loss Unconsolidated Subsidiary N/A N/A N/A N/A
Minority Interest N/A N/A N/A N/A
Net Income From Continuing Operations ($6,222,000) ($1,495,000) ($4,932,000) ($1,967,000)
Nonrecurring Events
Discontinued Operations N/A N/A N/A N/A
Extraordinary Items N/A N/A N/A $1,319,000
Effect Of Accounting Changes N/A N/A N/A N/A
Other Items N/A N/A N/A N/A
Net Income ($6,222,000) ($1,495,000) ($4,932,000) ($648,000)
Preferred Stock And Other Adjustments ($30,000) ($30,000) ($30,000) ($30,000)
Net Income Applicable To Common Shares ($6,252,000) ($1,525,000) ($4,962,000) ($678,000)
More filings for Calypte Biomedical Corp. available from EDGAR Online. Get a Free Trial to EDGAR Online Premium
EDGAR Online: Research People in this company | Full text Search
ADVERTISEMENT
da genügt eine normale brise optimismus nicht mehr, da muss man schon beinahe bescheuert sein, lol
viel schlimmer kann es auf alle fälle nicht kommen!